• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tocilizumab in severe COVID-19 pneumonia: A retrospective case-control study from eastern India.

作者信息

Mouli Tatikonda Chandra, Patnaik Rohit Kumar, Mishra Shakti Bedanta

机构信息

Department of Critical Care Medicine, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India.

出版信息

Indian J Anaesth. 2023 Jul;67(7):647-650. doi: 10.4103/ija.ija_157_23. Epub 2023 Jul 14.

DOI:10.4103/ija.ija_157_23
PMID:37601932
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10436727/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1251/10436727/8a5454578b82/IJA-67-647-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1251/10436727/8a5454578b82/IJA-67-647-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1251/10436727/8a5454578b82/IJA-67-647-g001.jpg

相似文献

1
Tocilizumab in severe COVID-19 pneumonia: A retrospective case-control study from eastern India.托珠单抗治疗重症新型冠状病毒肺炎：一项来自印度东部的回顾性病例对照研究。
Indian J Anaesth. 2023 Jul;67(7):647-650. doi: 10.4103/ija.ija_157_23. Epub 2023 Jul 14.
2
Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.皮质类固醇和托珠单抗可降低重症 COVID-19 肺炎患者的院内死亡率：一项西班牙医院的回顾性研究
Infect Dis (Lond). 2021 Apr;53(4):291-302. doi: 10.1080/23744235.2021.1884286. Epub 2021 Feb 23.
3
Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.托珠单抗在住院的中重度 COVID-19 肺炎患者中联合或不联合皮质类固醇的实际应用：一项回顾性队列研究。
PLoS One. 2021 Sep 10;16(9):e0257376. doi: 10.1371/journal.pone.0257376. eCollection 2021.
4
Adjuvant Tocilizumab in the Treatment of Patients with Moderate to Severe COVID-19 Pneumonia: An Observational Study.托珠单抗辅助治疗中重度 COVID-19 肺炎患者：一项观察性研究。
J Assoc Physicians India. 2022 Jan;70(1):11-12.
5
Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study.托珠单抗治疗重症新型冠状病毒肺炎住院患者的疗效：一项病例对照队列研究。
Pharmaceuticals (Basel). 2020 Oct 17;13(10):317. doi: 10.3390/ph13100317.
6
Tocilizumab in patients with severe COVID-19: a retrospective cohort study.托珠单抗治疗重症新型冠状病毒肺炎患者：一项回顾性队列研究
Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24.
7
Secondary Infection Risk in Patients With Severe COVID-19 Pneumonia Treated With Tocilizumab.托珠单抗治疗的重症新型冠状病毒肺炎患者的继发感染风险
Am J Ther. 2022;29(3):e275-e278. doi: 10.1097/MJT.0000000000001487. Epub 2022 Mar 4.
8
Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.托珠单抗对比标准治疗方案对中重度新型冠状病毒肺炎成年住院患者的疗效
Med Clin (Engl Ed). 2022 Apr 8;158(7):301-307. doi: 10.1016/j.medcle.2021.03.036. Epub 2022 May 3.
9
Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.托珠单抗对比标准治疗用于住院的中重度 COVID-19 肺炎成人患者的疗效。
Med Clin (Barc). 2022 Apr 8;158(7):301-307. doi: 10.1016/j.medcli.2021.03.005. Epub 2021 May 6.
10
Impact of Tocilizumab on Inflammatory Markers and Oxygen Status in Severe COVID-19 Patients: A Single Centre Retrospective Study.托珠单抗对重症 COVID-19 患者炎症标志物和氧合状态的影响：一项单中心回顾性研究。
Infect Disord Drug Targets. 2022;22(5):e210222201328. doi: 10.2174/1871526522666220221143920.

引用本文的文献

1
The association between tocilizumab therapy and the development of thrombosis in critically ill patients with COVID-19: a multicenter, cohort study.托珠单抗治疗与 COVID-19 重症患者血栓形成的关联：一项多中心队列研究。
Sci Rep. 2024 Feb 6;14(1):3037. doi: 10.1038/s41598-024-53087-z.

本文引用的文献

1
Barotrauma, invasive ventilation, and timing of tocilizumab as predictors of mortality along with inflammatory markers and comorbidities in critically ill COVID-19 patients: A retrospective study.在危重症新型冠状病毒肺炎患者中，气压伤、有创通气、托珠单抗的使用时机作为死亡率的预测因素以及与炎症标志物和合并症的关系：一项回顾性研究
Indian J Anaesth. 2021 Oct;65(10):755-759. doi: 10.4103/ija.ija_637_21. Epub 2021 Oct 29.
2
The association between four scoring systems and 30-day mortality among intensive care patients with sepsis: a cohort study.四种评分系统与脓毒症重症监护患者 30 天死亡率的相关性：一项队列研究。
Sci Rep. 2021 May 27;11(1):11214. doi: 10.1038/s41598-021-90806-2.
3
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.
托珠单抗治疗重症 COVID-19 肺炎住院患者。
N Engl J Med. 2021 Apr 22;384(16):1503-1516. doi: 10.1056/NEJMoa2028700. Epub 2021 Feb 25.
4
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.COVID-19 重症患者的白细胞介素 6 受体拮抗剂。
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
5
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.托珠单抗对重症或危重症 2019 冠状病毒病患者 15 天临床结局的影响：随机对照试验。
BMJ. 2021 Jan 20;372:n84. doi: 10.1136/bmj.n84.
6
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.托珠单抗治疗新冠肺炎合并肺炎住院患者的疗效。
N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17.
7
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
8
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.托珠单抗对比常规治疗用于 COVID-19 成人患者伴中重度肺炎的随机临床试验
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
9
Indian Society of Anaesthesiologists (ISA National) Advisory and Position Statement regarding COVID-19.印度麻醉医师协会（印度国家协会）关于2019冠状病毒病的咨询意见和立场声明。
Indian J Anaesth. 2020 Apr;64(4):259-263. doi: 10.4103/ija.IJA_288_20. Epub 2020 Mar 28.
10
Cytokine release syndrome in severe COVID-19.重症新型冠状病毒肺炎中的细胞因子释放综合征
Science. 2020 May 1;368(6490):473-474. doi: 10.1126/science.abb8925. Epub 2020 Apr 17.